HB Wealth Management LLC Boosts Holdings in Johnson & Johnson $JNJ

HB Wealth Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 303,233 shares of the company’s stock after purchasing an additional 6,789 shares during the quarter. HB Wealth Management LLC’s holdings in Johnson & Johnson were worth $74,122,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of JNJ. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $954,000. World Investment Advisors lifted its stake in shares of Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after purchasing an additional 26,450 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 9.8% during the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock worth $17,738,000 after purchasing an additional 8,533 shares during the last quarter. Benchmark Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $554,000. Finally, Sienna Gestion increased its stake in Johnson & Johnson by 9.3% in the third quarter. Sienna Gestion now owns 142,127 shares of the company’s stock valued at $24,027,000 after purchasing an additional 12,073 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. HSBC set a $290.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Raymond James Financial raised their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 15th. Finally, Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $257.13.

Johnson & Johnson Stock Down 1.4%

Shares of NYSE JNJ opened at $259.31 on Tuesday. The stock has a fifty day moving average price of $233.72 and a 200 day moving average price of $231.37. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $154.21 and a 12-month high of $263.10. The company has a market cap of $624.22 billion, a P/E ratio of 29.98, a P/E/G ratio of 2.58 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The company’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.